Abstract
BackgroundAnti-programmed death (PD)-1 therapy has recently been used in recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC). The long-term survival and its biomarkers responding to anti-PD-1 treatment in patients with R/M...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have